Streamlining Radioembolization for Small HCC

Launched by SEOUL NATIONAL UNIVERSITY HOSPITAL · May 11, 2025

Keywords

ClinConnect Summary

This clinical trial is looking at a treatment called radioembolization for patients with a type of liver cancer known as hepatocellular carcinoma (HCC). The study aims to see if we can safely skip a specific scan (called an MAA scan) before the treatment for certain patients. The researchers believe that by using specific selection criteria, they can streamline the process of radioembolization and make it easier for patients who meet these criteria.

To be eligible for this trial, patients should have HCC that is 5 centimeters or smaller and have certain types of blood vessel features within the tumor. They also need to have a specific level of liver function and meet other health criteria. Patients will be monitored closely throughout the trial to ensure their safety. This trial is not yet recruiting participants, but it is important for patients with small HCC to know about the potential for a more efficient treatment process if they meet the study criteria.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • HCC can be diagnosed by AASLD guideline
• • hepatocellular carcinoma 5cm or smaller
• • dysmorphic intratumoral vessels 3mm or smaller
• • Child-Pugh class A
• • ECOG 0 or 1
• • the following lab should be met. A. Leukocytes ≥ 1,000/µL and ≤ 20,000/µL B. Hemoglobin ≥ 6.0 g/dL (transfusion allowed to meet this criterion) C. Total bilirubin ≤ 2.0 mg/dL D. Platelet ≥ 40,000/µL E. International normalized ratio (INR) ≤ 2.0 for patients not taking anticoagulants F. Aspartate transaminase (AST) ≤ 800 IU/L (i.e., ≤ 20X upper normal limit) G. Alanine transaminase (ALT) ≤ 800 IU/L (i.e., ≤ 20X upper normal limit) H. Creatinine ≤ 2.5 mg/dL (if patient is receiving hemodialysis, no upper limit of creatinine)
• Exclusion Criteria:
• • hepatic vein invasion on CT/MRI
• • hepatic vein enhancement on arterial phase of CT/MRI
• • TIPS
• • dysmorphic intratumoral vessels \> 3mm
• • main portal vein invasion
• • significant COPD or interstitial lung disease
• • biliary stent or bilioenteric anastomosis